EP1231913A2 - Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds - Google Patents
Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compoundsInfo
- Publication number
- EP1231913A2 EP1231913A2 EP00951029A EP00951029A EP1231913A2 EP 1231913 A2 EP1231913 A2 EP 1231913A2 EP 00951029 A EP00951029 A EP 00951029A EP 00951029 A EP00951029 A EP 00951029A EP 1231913 A2 EP1231913 A2 EP 1231913A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- fatty acid
- acid compound
- cyclooxygenase
- administered
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 fatty acid compounds Chemical class 0.000 title claims abstract description 215
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 187
- 239000000194 fatty acid Substances 0.000 title claims abstract description 187
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 187
- 108010037462 Cyclooxygenase 2 Proteins 0.000 title claims abstract description 48
- 230000001404 mediated effect Effects 0.000 title claims abstract description 40
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 102000010907 Cyclooxygenase 2 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 claims abstract description 142
- 230000008569 process Effects 0.000 claims abstract description 130
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 46
- 208000035475 disorder Diseases 0.000 claims abstract description 42
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 206010061218 Inflammation Diseases 0.000 claims abstract description 26
- 230000004054 inflammatory process Effects 0.000 claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 26
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 229910018828 PO3H2 Inorganic materials 0.000 claims abstract 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 24
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 23
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 22
- 150000004714 phosphonium salts Chemical class 0.000 claims description 20
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 19
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 150000001350 alkyl halides Chemical class 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 8
- 230000037213 diet Effects 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 229910006069 SO3H Inorganic materials 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000007882 Gastritis Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006811 Bursitis Diseases 0.000 claims description 3
- 208000027932 Collagen disease Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000007101 Muscle Cramp Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010028836 Neck pain Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 3
- 206010036600 Premature labour Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 206010038910 Retinitis Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 206010043269 Tension headache Diseases 0.000 claims description 3
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 229910052792 caesium Inorganic materials 0.000 claims description 3
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 208000013315 neuromuscular junction disease Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 208000026440 premature labor Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 abstract description 12
- 150000002431 hydrogen Chemical group 0.000 abstract description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 150000001299 aldehydes Chemical class 0.000 description 13
- JHXAZBBVQSRKJR-UHFFFAOYSA-N coriolic acid Natural products CCCCCC(=O)C=CC=CCCCCCCCC(O)=O JHXAZBBVQSRKJR-UHFFFAOYSA-N 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 150000004702 methyl esters Chemical class 0.000 description 13
- HNICUWMFWZBIFP-BSZOFBHHSA-N 13-HODE Chemical compound CCCCCC(O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-BSZOFBHHSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 7
- 229940124599 anti-inflammatory drug Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical group CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 229910052756 noble gas Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HNICUWMFWZBIFP-IRQZEAMPSA-N 13(S)-HODE Chemical compound CCCCC[C@H](O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-IRQZEAMPSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 125000004149 thio group Chemical group *S* 0.000 description 2
- 229940081852 trilinolein Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
- NOCWDMQAHCQAKS-UHFFFAOYSA-N 2-hydroxyoctadeca-2,4-dienoic acid Chemical class CCCCCCCCCCCCCC=CC=C(O)C(O)=O NOCWDMQAHCQAKS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- AJFTZWGGHJXZOB-UHFFFAOYSA-N DuP 697 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(Br)=C1 AJFTZWGGHJXZOB-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101150062589 PTGS1 gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001306211 Xeranthemum annuum Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HFNPVFKUZYCDIB-UHFFFAOYSA-N methyl 11-bromoundecanoate Chemical compound COC(=O)CCCCCCCCCCBr HFNPVFKUZYCDIB-UHFFFAOYSA-N 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical compound [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
Definitions
- This invention generally relates to a process for preventing or treating medical disorders by reducing the activity of cyclooxygenase. More specifically, this invention relates to a process for preventing or treating inflammation and other cyclooxygenase-2 ("COX-2") mediated disorders by inhibiting COX-2 using a conjugated fatty acid compound (most preferably, a conjugated eicosadienoic acid compound or a coriolic acid compound). In a particularly preferred embodiment, COX-2 is selectively inhibited in preference to cyclooxygenase- 1 ("COX-1").
- This invention further relates to a method for preparing fatty acid compounds, which, in turn, may be used to treat COX-2 mediated disorders.
- Inflammation is a defense mechanism of organisms caused by a physical or chemical stimulation, such as an injury to tissue.
- the classic symptoms of inflammation include, for example, pain, heat, redness, swelling, and sometimes loss of tissue function.
- Histologically, inflammation is characterized by, for example, hyperemia (i. e. , the presence of excess blood in a region of an organism), stasis (i. e. , the stoppage of the flow of blood in a region of an organism), changes in blood composition, changes in the walls of small blood vessels (typically in the form of expansion and perforation), and/or various exudations (i.e., leakages of blood components from the blood vessels and the deposition of such components in tissue or on tissue surfaces).
- hyperemia i. e. , the presence of excess blood in a region of an organism
- stasis i. e. , the stoppage of the flow of blood in a region of an organism
- changes in blood composition changes in the walls of small blood vessels (typically in
- anti-inflammatory drugs are available for inhibiting inflammatory symptoms and alleviating the tissue destruction caused by inflammation.
- One general class of anti- inflammatory drugs consists of adrenocortical hormones (i.e., steroidal anti- inflammatory drugs).
- steroidal anti-inflammatory drugs provide strong anti- inflammatory action, they also tend to exhibit strong side-effects, such as hypertension, decreased immunity, hyperglycemia, osteoporosis, myopathy, cataracts, growth arrest, and electrolyte abnormalities. These side-effects are particularly problematic when such drugs are used over a long period of time.
- a second general class of anti-inflammatory drugs consists of non-steroidal compositions.
- Non-steroidal anti-inflammatory drugs typically are directed to inhibiting enzymes in the arachidonic metabolic cascade which forms prostaglandins. This approach is effective for reducing inflammation because prostaglandins (particularly PGG 2 , PGH 2 , and PGE 2 ) play a major role in the inflammation process.
- One enzyme which is often targeted by non-steroidal anti-inflammatory drugs is cyclooxygenase (sometimes referred to as "COX”), which performs the initial reaction in the arachidonic metabolic cascade. See Smith, W.L., "Prostanoid
- COX-1 is found in nearly every tissue in the body, including the stomach, kidney, heart, brain, liver, and spleen. It is normally associated with the formation of homeostatic prostaglandins, which are linked to many normal tissue functions, such as gastric and renal functions.
- COX-2 on the other hand, is typically found in sites of inflammation, and is associated with pro-inflammatory prostaglandin production. Besides causing inflammation, this pro-inflammatory prostaglandin production also has been linked to other diseases, such as cancer. Belury, M.A., "Conjugated Dienoic Linoleate: A Polyunsaturated Fatty Acid with Unique Chemoprotective Properties," Nutrition Reviews, vol. 53, no. 4, 83-89 (1995). Although aspirin and many other conventional non-steroidal anti- inflammatory drugs reduce inflammation (and other COX-2 mediated disorders) by inhibiting of COX-2, they also tend to indiscriminately inhibit COX-1.
- This invention provides for a safe, simple, and effective process for preventing or treating inflammation and other COX-2 mediated disorders in an organism (human or otherwise) by inhibiting the COX-2 enzyme through the administration of a conjugated fatty acid compound.
- This invention also provides for a process for preventing or treating inflammation and other COX-2 mediated disorders in an organism by selective inhibition of COX-2 in preference to COX-1, thereby permitting the inhibition of COX-2 with fewer of the adverse side-effects normally associated with aspirin and many other conventional COX-2 inhibitors known in the art.
- this invention is directed to a process for preventing or treating a cyclooxygenase-2 mediated disorder in an organism having a cyclooxygenase-2 mediated disorder or disposed to having a cyclooxygenase-2 mediated disorder.
- This process comprises administering a fatty acid compound to the organism in an amount effective to prevent or treat the COX-2 mediated disorder by inhibiting COX-2.
- the fatty acid compound has formula (I) or is a pharmaceutically acceptable salt thereof:
- the fatty acid compound has formula (VI) or is a pharmaceutically acceptable salt thereof:
- R 6 is hydrogen, hydrocarbyl, or substituted hydrocarbyl
- R 7 is -OH, -SO 3 H, -SH, -NH 2 , -PO 3 H 2 , or halogen
- v is from 7 to 11
- the sum of v and w is from 11 to 15.
- This invention also provides for a simple process for preparing fatty acid compounds which may be used to prevent or treat COX-2 mediated disorders.
- One advantage of this process is that it typically does not produce a significant amount of undesirable fatty acid byproducts (e.g., undesirable isomers).
- the process comprises combining a ylide with an aldehyde.
- the fatty acid product has formula (I):
- R 1 , R 2 , R 3 , and R 4 are independently hydrocarbyl or substituted hydrocarbyl; m is from 6 to 11; the sum of n and m is from 13 to 16; x is 0 or 1; and the sum of x and y is l.
- Figure 1 shows a reaction scheme which may be used to prepare a fatty acid compound containing an unsubstituted fatty acid residue having from 19 to 22 carbons.
- This scheme comprises forming a ylide, and reacting the ylide with an aldehyde.
- a method for preventing or treating inflammation and other COX-2 mediated disorders in an organism by inhibiting (i.e., reducing the activity of) the COX-2 enzyme through the administration of a conjugated fatty acid compound.
- the fatty acid compound preferably has a COX-2 IC 50 of less than about 100 ⁇ M, more preferably less than about 60 ⁇ M, even more preferably less than about 1.5 ⁇ M, still even more preferably less than about 1 ⁇ M, and most preferably less than 0.5 ⁇ M.
- the fatty acid compound also preferably has a COX-1 IC 50 which is greater than about 0.5 ⁇ M, more preferably greater than about 1 ⁇ M, even more preferably greater than about 1.5 ⁇ M, still even more preferably greater than about 60 ⁇ M, and most preferably greater than about 100 ⁇ M.
- the "IC 50 " value represents the concentration of the fatty acid compound required to reduce by 50% (as compared to an uninhibited control) the activity of the COX enzyme to produce prostaglandin E 2 ("PGE 2 ”) in the presence of arachidonic acid.
- the fatty acid compound also selectively inhibits COX-2 in preference to COX-1.
- the fatty acid compound which is administered to the organism has a COX-2 IC 50 which is less than the COX-1 IC 50 .
- the ratio of the COX-1 IC 50 to the COX-2 IC 50 preferably is at least about 1.5, more preferably at least about 2, even more preferably at least about 2.5, still even more preferably at least about 3, and most preferably at least about 3.5.
- the fatty acid compound which is administered is a pro-drug (i.e., the fatty acid compound reacts following administration to form a different fatty acid compound, which, in turn, acts to inhibit the COX-2 enzyme).
- an ester of a fatty acid e.g., the ethyl ester of cl l,tl3-eicosadienoic acid
- it may hydrolyze during digestion to form the corresponding free fatty acid (e.g., cl l,tl3-eicosadienoic acid) and an alcohol (e.g., ethanol); in that instance, the compound which actually acts to inhibit the COX-2 enzyme is the free fatty acid.
- the fatty acid compound which actually acts to inhibit the COX-2 enzyme has a COX-2 IC 50 which is less than the COX-1 IC 50 .
- the fatty acid compound which actually acts to inhibit the COX-2 enzyme has a ratio of the COX-1 IC 50 to the COX-2 IC 50 which is at least about 1.5, more preferably at least about 2, even more preferably at least about 2.5, still even more preferably at least about 3, and most preferably at least about 3.5.
- Two types of fatty acid compounds have been found in accordance with this invention to be particularly suitable for inhibiting COX-2: (1) a conjugated fatty acid compound comprising an unsubstituted fatty acid residue which has from 19 to 22 carbon atoms; and (2) a conjugated fatty acid compound comprising a fatty acid residue which has from 18 to 22 carbon atoms and is substituted with one of the following functional groups: a hydroxyl group (-OH), a sulfo group (-SO 3 H), a thio group (-SH), an amino group (-NH 2 ), a phosphono acid group (-PO 3 H 2 ), or a halogen.
- a conjugated fatty acid compound comprising an unsubstituted fatty acid residue which has from 19 to 22 carbon atoms
- a conjugated fatty acid compound comprising a fatty acid residue which has from 18 to 22 carbon atoms and is substituted with one of the following functional groups: a hydroxyl group (-OH), a sul
- the unsubstituted conjugated fatty acid compound generally has the following formula (I) or is a pharmaceutically acceptable salt thereof:
- R 1 is hydrogen, hydrocarbyl, or substituted hydrocarbyl; and the sum of n and m is from 13 to 16.
- m is from 6 to 11.
- the unsubstituted fatty acid compound is a glyceride, most preferably a triglyceride.
- R 1 is hydrogen or a saturated hydrocarbyl (i.e., the hydrocarbyl contains no carbon-carbon double or triple bonds).
- R 1 is hydrogen or a saturated hydrocarbyl containing no greater than 6 carbon atoms (e.g., methyl (-CH 3 ), ethyl (-CH 2 CH 3 ), propyl (-(CH 2 ) 2 CH 3 ), isopropyl (-CH(CH 3 ) 2 ), butyl (-(CH 2 ) 3 CH 3 ), pentyl (-
- R 1 is methyl. Most preferably, R 1 is ethyl or hydrogen.
- the fatty acid compound contains an eicosadienoic acid residue (i.e., the sum of n and m is 14).
- m preferably is from 7 to 9 (most preferably 9).
- the fatty acid compound is the methyl ester of cl l,tl3-eicosadienoic acid ("c" meaning cis, and "t” meaning trans), i.e., the compound having formula (VIII):
- the fatty acid compound is the ethyl ester of cl l,t 13 -eicosadienoic acid, i.e., the compound having formula (LX):
- the fatty acid compound is cl l,tl3-eicosadienoic acid (i.e. , the compound having formula (VII)) or a pharmaceutically acceptable salt thereof:
- conjugated eicosadienoic acid reduces the activity of COX-2. It also is selective toward inhibiting COX-2 in preference to COX-1. Thus, it may be administered to treat COX-2 mediated disorders, and advantageously causes fewer (if any) of the side effects normally associated with less selective anti-inflammatory drugs (e.g., aspirin).
- the methyl ester of eicosadienoic acid i.e., formula (VIII)
- COX-2 inhibition may still be achieved by administering the ester as a pro-drug in a manner such that the ester will form the free fatty acid following administration. For example, if the ester is administered orally to a warm-blooded animal, it will typically hydrolyze during digestion to form the free fatty acid.
- the conjugated fatty acid compound is prepared by forming a ylide, and reacting the ylide with an aldehyde.
- Figure 1 shows a general reaction scheme for such an embodiment.
- the benefits of using this reaction scheme include, for example, the fact that it produces a product composition which contains the desired conjugated fatty acid compound, but few (if any) undesirable fatty acid byproducts.
- This reaction scheme is particularly preferred for forming a carbon-carbon double bond having a cis configuration because the reaction tends to be highly selective toward forming such a configuration, especially at low reaction temperatures (i.e., a reaction temperature which is no greater than about -30°C).
- the ylide used to prepare the conjugated fatty acid compound preferably has formula (II):
- the ylide has a structure wherein R 2 , R 3 , and R 4 are each phenyl (-C 6 H 5 ) or phenyl substituted with at least one hydrocarbyl (most preferably, R 2 , R 3 , and R 4 are each unsubstituted phenyl).
- m is 9.
- x is 0. Combinations of these embodiments are also particularly preferred.
- the ylide preferably is formed by a process comprising first combining a phosphine compound with a haloalkane to form a phosphonium salt having formula (XI):
- the phosphine compound has formula (IV):
- R 2 , R 3 , and R 4 are as defined above for the ylide; and R 5 is halogen (preferably bromine).
- R 5 is halogen (preferably bromine).
- the molar ratio of the phosphine compound to the haloalkane preferably is from about 1.1:1 to about 1.5:1, more preferably from about 1.1 :1 to about 1.3:1, and most preferably about 1.25:1).
- Large excesses of either the phosphine compound or the haloalkane preferably are avoided due to the extra separation costs to remove such excesses from the product mixture.
- the reaction of the phosphine compound with the haloalkane may be conducted in a wide range of solvents which can solubilize the phosphine reagent, the haloalkane, and the phosphonium salt product.
- Suitable solvents typically include, for example, acetonitrile, toluene, dichloromethane, benzene, acetone, N,N- dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and hexamethylphosphoric triamide (HMPA).
- Protic solvents e.g., methanol, ethanol, and water
- the solvent has a dielectric constant which is from about 2 to about 40 at about 20°C and atmospheric pressure (dielectric constants for many compounds are well known in the art, and may be found in, for example, Handbook of Chemistry and Physics (CRC Press, Inc., Boca Raton, Florida) (incorporated herein by reference)).
- the solvent also preferably has a boiling point at atmospheric pressure of at least about 50°C, and more preferably at least about 80°C. Preferably, from about 2 to about 100 ml (more preferably from about 5 to about 25 ml, and most preferably from about 5 to about 10 ml) of solvent are used per each mmole of the phosphine compound.
- the environment in which the phosphine compound and haloalkane are reacted preferably is an inert environment (i.e., an environment that essentially does not react with the reagents or products of the reaction). This environment may contain, for example, nitrogen, a noble gas (e.g., helium, argon, and neon), or a combination thereof.
- the more preferred environment contains a noble gas (most preferably argon) rather than nitrogen due to the fact that nitrogen may react with components of the reaction mixture under certain conditions. In other embodiments (particularly large scale embodiments), however, the environment contains nitrogen due to its relatively low cost. In any event, the environment contains essentially no oxygen gas or water, and more preferably contains no oxygen gas or water (oxygen gas tends to oxidize the phosphine compound, and water tends to hydrolyze the resulting ylide).
- the temperature preferably is sufficient to dissociate the halogen from the rest of the haloalkane compound. Typically, the temperature is at least about 50°C, more preferably from about 50 to about 100°C, and most preferably from about 80 to about 100°C.
- Such a temperature may often be achieved by refluxing the reaction mixture at about atmospheric pressure.
- the reaction time varies widely, and depends, for example, on the temperature at which the reaction is conducted (in general, the greater the temperature, the faster the reaction rate) and the concentration of the reagents (in general, the greater the reagent concentrations, the faster the reaction rate). Typical minimum reaction times range from about 6 hours to about 5 days, with the most typical reaction time being about 3 days.
- the solvent preferably is evaporated and the excess phosphine compound preferably is removed from the remaining reaction mixture. Removal of the excess phosphine compound may be achieved using, for example, silica gel chromatography by methods well known in the art. Alternatively, for example, the excess phosphine compound may be removed from the reaction mixture by extracting the phosphine compound from the reaction mixture with a non-polar solvent. This extraction is typically performed at a temperature of at least about 20°C.
- the extraction solvent has a dielectric constant such that the phosphonium salt is essentially insoluble in the solvent. It is particularly preferred for the extraction solvent to have a dielectric constant of less than about 2 at about 20°C and atmospheric pressure.
- Hydrocarbon solvents e.g., hexane and pentane
- the amount of extraction solvent may vary widely. In most instances, it is preferred to use from about 50 to about 100 ml of extraction solvent per gram of the phosphine compound initially loaded.
- the phosphine compound is removed from the reaction mixture with a solvent containing both a polar component and a non-polar component. This extraction may be conducted in addition to (or as an alternative to) an extraction with an exclusively non-polar solvent.
- the polar component may be, for example, dichloromethane. Such a polar component typically enhances the amount of phosphine compound extracted from the reaction mixture.
- the polar component preferably makes up no greater than about half the total volume of the extraction solvent. Preferably, from about 50 to about 100 ml of polar/nonpolar extraction solvent is used per gram of the phosphine compound initially loaded.
- the phosphonium salt is combined with a base to deprotonate the phosphonium salt.
- bases include, for example, lithium hexamethyldisilazane (LiHMDS), butyllithium, sodium hydride, and alkoxides.
- the most preferred bases are hindered bases (i.e., a base that essentially will not attack an electrophile, but can accept an electron), such as LiHMDS.
- the number of moles of base preferably is substantially equal to the number of moles of phosphonium salt.
- the reaction preferably is conducted in a solvent which has a dielectric constant sufficient to dissolve the phosphonium salt.
- suitable solvents include, for example, N,N-dimethylformamide (DMF), tetrahydrofuran (THF), hexamethylphosphoric triamide (HMPA), and combinations thereof.
- DMF N,N-dimethylformamide
- THF tetrahydrofuran
- HMPA hexamethylphosphoric triamide
- from about 2 to about 100 ml (more preferably from about 5 to about 25 ml, and most preferably from about 5 to about 10 ml) of solvent are used per each mmole of phosphonium salt.
- the reaction mixture preferably is kept under an inert environment.
- the temperature preferably is maintained at from about -78 (using, for example, liquid nitrogen as the cooling source) to about -30°C (using, for example, an electronic cooling bath), and more preferably is maintained at from about -78 to about -50°C. Greater temperatures are less preferred because the ylide product at such temperatures tends to decompose to form a phosphonium oxide.
- the preferred reaction time is dependent on, for example, reaction temperature. At temperatures of from about -78 to about -50°C, the preferred reaction time typically is from about 30 to about 60 minutes. Either during or after the ylide formation (most preferably after the ylide formation), the reaction mixture is combined with an aldehyde to form the desired fatty acid compound. Because the ylide is highly reactive, it typically is not separated from the reaction mixture before being combined with the aldehyde.
- the aldehyde preferably has formula (III):
- n is as defined above for the fatty acid compound (i.e., formula (I)); and y is 0 or 1, such that the sum of x (as defined for formula (II)) and y is 1.
- the preferred amount of aldehyde is dependent on the amount of phosphonium salt used to form the ylide.
- the moles of aldehyde added preferably is slightly less than the number of moles of phosphonium salt used in the deprotonation reaction to form the ylide due to the fact that the aldehyde is generally more expensive.
- the molar ratio of aldehyde to phosphonium salt is from about 1:1.1 to about 1:1.5.
- the reaction preferably is conducted at from about -78 to about -30°C for from about 30 to about 120 minutes under an inert atmosphere. More preferably the temperature ranges from about -50°C to about -78°C, and most preferably is about -78°C. As noted above, use of such low temperatures tends to promote the formation of a cis carbon-carbon double bond.
- the reaction mixture preferably is gradually warmed by, for example, placing the reaction mixture in an environment having a temperature of from about 20 to about 25°C.
- the excess ylide preferably is hydrolyzed, using, for example, an aqueous solution of ammonium acetate or ammonium chloride having a pH of about 7.
- the fatty acid compound may be separated from the reaction mixture using any of the various conventional separation methods known in the art. See, e.g., Example 1 below, which uses extraction with a non-polar organic solvent, followed by chromatographic separation on a silica gel column.
- the ester is further hydrolyzed to form the free fatty acid before being administered as a treatment.
- Hydrolysis of the ester may be carried out by, for example, acid-catalyzed or base-catalyzed hydrolysis. Many variations of such hydrolysis methods are well known in the art.
- the hydrolysis is a base-catalyzed reaction carried out in an aqueous solution containing a weak base, such as sodium bicarbonate, triethylamine, cesium carbonate, and potassium carbonate, with potassium carbonate being most preferred.
- a weak base such as sodium bicarbonate, triethylamine, cesium carbonate, and potassium carbonate, with potassium carbonate being most preferred.
- an alcohol preferably is added to the solution to solubilize the ester.
- the alcohol has the formula R'-OH, wherein R 1 is as defined in formula (I) (for example, if the ester is a methyl ester, the alcohol is methanol; if the ester is an ethyl ester, the alcohol is ethanol; etc.).
- R 1 is as defined in formula (I)
- the hydrolysis preferably is performed in a non-oxidizing atmosphere (i.e., the atmosphere consists essentially of a non-oxidizing gas(es), such as N 2 and/or a noble gas.
- the substituted conjugated fatty acid compound generally has the following formula (VI) or is a pharmaceutically acceptable salt thereof:
- R 6 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;
- R 7 is an acidic group; and the sum of v and w is from 11 to 15.
- v is from 7 to 11.
- R 7 is preferably -OH, -SO 3 H, -SH, -NH 2 , -PO 3 H 2 , or halogen, with -OH being most preferred.
- the fatty acid compound is a glyceride, and most preferably a triglyceride.
- R 6 is hydrogen or a saturated hydrocarbyl.
- R 6 is hydrogen or a saturated hydrocarbyl containing no greater than 6 carbon atoms (e.g., methyl (-CH 3 ), ethyl (-CH 2 CH 3 ), propyl (-(CH 2 ) 2 CH 3 ), isopropyl (-CH(CH 3 ) 2 ), butyl (-(CH 2 ) 3 CH 3 ), pentyl (-
- R 6 is methyl. In another even more preferred embodiment, R 6 is ethyl. In a further even more preferred embodiment, R 6 is hydrogen.
- the sum of v and w is 11. Even more preferably, the sum of v and w is 11, and R 7 is -OH. Still even more preferably, the fatty acid compound is coriolic acid (i.e., v is 7, w is 4, R 6 is hydrogen, and R 7 is -OH), a salt of coriolic acid, or an ester of coriolic acid. In the most preferred embodiment, the fatty acid compound is 13S-hydroxy-c9, til -coriolic acid (i.e., the compound having formula (X)) or a pharmaceutically acceptable salt thereof:
- coriolic acid like eicosadienoic acid selectively inhibits COX-2 in preference to COX-1.
- side effects normally associated with less selective anti-inflammatory drugs e.g., aspirin
- coriolic acid may be reduced (or altogether avoided) by using coriolic acid.
- the fatty acid compound of formula (VI) and salts thereof may be either administered in addition to the fatty acid compound of formula (I) or salts thereof, or as an alternative to the fatty acid compound of formula (I) or salts thereof.
- hydroxyoctadecadienoic acids occur naturally in vegetable and animal tissues, and can be isolated from them (e.g. , in vegetable extracts of nettle roots, such acids have been reported to be present as both free acids and as ester components of glycerides, ceramides, and phospholipids).
- Such acids also can be synthesized from oleic acid and from linoleic acid. See, e.g., Streber, U.S. Patent No. 5,102,912 (incorporated herein by reference).
- Coriolic acid in particular, may be prepared from linoleic acid by lipooxygenation under oxygen pressure (2.5 bar), followed by reduction of the hydroperoxide.
- oxygen pressure 2.5 bar
- Coriolic acid may be prepared from linoleic acid by lipooxygenation under oxygen pressure (2.5 bar), followed by reduction of the hydroperoxide.
- Coriolic acid also may be prepared from an optically active lactol starting material, as described in Bloch, R. and Perfetti, M.T., "An Efficient Synthesis of 13(S)-hydroxy-9z,l le-octadecadienoic (Coriolic) Acid," Tetrahedron Letters, vol. 31, no. 18, pp. 2577-80 (1990) (incorporated herein by reference).
- coriolic acid may be prepared, for example, from trilinolein, as described in Gargouri, M. and Legoy, M.D., "Chemoenzymatic Production of (+)- Coriolic Acid from Trilinolein: Coupled Synthesis and Extraction," JAOCS, vol. 74, no. 6, pp.
- Coriolic acid further may be isolated from plants such as, for example, from the oil of Xeranthemum annuum seeds (see Powel, R.C., Smith, C.R., and Wolff, LA., "Geometric Configuration and Etherification Reactions of Some Naturally Occurring 9-Hydroxy- 10,12- and 13-Hydroxy-9,l l-Octadecadienoic Acids," J Org. Chem., 32, 1442-46 (1966) (incorporated herein by reference)).
- Example 3 below further illustrates the preparation of coriolic acid.
- conjugated fatty acid compounds may generally be administered (alone or in combination) to prevent or treat all types of inflammation and other COX-2 mediated disorders.
- these fatty acid compounds may be used to treat swelling, fever, redness of the skin, aches (e.g., tension headaches, migraine headaches, postoperative pain, dental pain, muscular pain, back pain, neck pain, and pain resulting from cancer), arthritis (e.g., rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, and juvenile arthritis), arthritic symptoms, skin conditions (e.g., dermatitis, psoriasis, eczema, and burns), infections, gastrointestinal conditions (e.g., inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, and ulcerative co
- the selective fatty acid compounds of this invention are typically well-suited for treating organisms which have preexisting conditions often associated with COX-1 inhibition, such as peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, recurring gastrointestinal lesions, gastrointestinal bleeding, coagulation or other bleeding disorders, and kidney disease (e.g., impaired renal function).
- the selective fatty acid compounds of this invention are also typically well-suited for treating organisms that are (1) susceptible to non-steroidal anti-inflammatory drug induced asthma, (2) about to have a surgery, and/or (3) taking anticoagulants.
- the fatty acid compounds described herein generally may be used to treat a wide variety of organisms, particularly warm-blooded organisms.
- these fatty acid compounds may be used to treat humans, compamon animals (e.g., dogs and cats), farm animals (e.g., horses, cattle, goats, pigs, rabbits, and sheep), mice, rats, and wild animals.
- compamon animals e.g., dogs and cats
- farm animals e.g., horses, cattle, goats, pigs, rabbits, and sheep
- mice e.g., horses, cattle, goats, pigs, rabbits, and sheep
- mice e.g., mice, rats, and wild animals.
- the fatty acid compounds are used to treat warmblooded animals having a cyclooxygenase-2 mediated disorder or disposed to having a cyclooxygenase-2 mediated disorder.
- the mode of administration may vary widely.
- the fatty acid compounds of this invention may be administered by any acceptable means which results in the prevention, reduction, or elimination of the targeted inflammation or other COX-2 mediated disorder.
- such fatty acid compounds may be administered orally (e.g., in the form of a tablet, capsule, syrup, solution, emulsion, food supplement, or drink supplement); parenterally (e.g., via subcutaneous injection, intramuscular injection, intrasternal injection, intravenous injection, or infusion techniques); topically (e.g., in the form of an ointment or eye drops), particularly when the inflammation is localized near the surface of the skin; via inhalation (e.g., in the form of an inhalant); via nasal spray; or rectally (e.g., in the form of a suppository).
- the fatty acid compound Before being administered, the fatty acid compound may be combined with a conventionally used pharmaceutically acceptable compound(s) which is compatible with the fatty acid compound.
- This pharmaceutically acceptable compound may be, for example, another drug, such as, for example, a lipooxygenase.
- the pharmaceutically acceptable compound may also be, for example, an adjuvant, excipient, corrigent (e.g., a flavoring agent), coloring agent, preserving agent, or other additive.
- the excipient may be, for example, an inert diluent (e.g., calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate, peanut oil, liquid paraffin, or olive oil), a binder (e.g., starch, gelatin, or acacia), a granulating or disintegrating agent (e.g., corn starch or alginic acid), or a lubricant (e.g., magnesium stearate, stearic acid, or talc).
- the fatty acid compound may also be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby sustaining action over a longer period.
- Such a coating may contain, for example, glyceryl monostearate or glyceryl distearate.
- a non-irritating excipient e.g., cocoa butter or a polyethylene glycol
- cocoa butter or a polyethylene glycol e.g., cocoa butter or a polyethylene glycol
- the fatty acid compound may be administered with one or more other fatty acid compounds, and therefore does not have to necessarily be isolated from other fatty acid compounds before being administered. Further, when administering the fatty acid compound orally, the fatty acid compound typically may be administered in the presence of other compounds that are ordinarily found in foods and beverages (e.g., proteins, sugars, fats, vitamins, etc.).
- the preferred dosage will vary, depending generally on factors such as the sex, age, weight, diet, rate of excretion, and physical condition of the recipient; the form of the fatty acid compound; the time and route of administration; the severity, type, stage, and location of the inflammation or other COX-2 mediated disorder to be prevented or treated; and the existence of any concurrent treatments.
- the fatty acid compound is administered to the organism in an amount which is effective to prevent or treat the targeted cyclooxygenase-2 mediated disorder by reducing the activity of COX-2.
- the preferred daily dose typically is from about 0.0001 to about 2 g/Kg (i.e., grams of fatty acid compound per kilograms of recipient), more preferably from about 0.001 to about 2 g/Kg, and most preferably from about 0.001 to about 1 g/Kg.
- the fatty acid compound make up from about 1 to about 10,000 ppm by weight (more preferably from about 100 to about 10,000 ppm by weight, and most preferably from about 1,000 to about 10,000 ppm by weight) of the recipient's diet when administered orally. It should be recognized that in most instances, the foregoing upper limits are not particularly critical because the fatty acid compounds used herein are generally relatively non-toxic.
- Oral dosages typically are administered from 1 to 6 times per day, and more typically from 1 to 3 times per day. DEFINITIONS
- hydrocarbyl is defined as a group consisting exclusively of carbon and hydrogen.
- the hydrocarbyl may be branched or unbranched, may be saturated or unsaturated, and may comprise one or more rings.
- Suitable hydrocarbyl moieties include alkyl, alkenyl, alkynyl, and aryl moieties. They also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbyl groups, such as alkaryl, alkenaryl and alkynaryl.
- substituted hydrocarbyl is defined as a hydrocarbyl wherein at least one hydrogen atom has been substituted with (1) an atom other than hydrogen and carbon, or (2) a group of atoms which contains at least one atom other than hydrogen and carbon.
- the hydrogen atom may be replaced by a halogen atom, such as a chlorine or fluorine atom.
- the hydrogen atom alternatively may be substituted by an oxygen atom to form, for example, a hydroxy group, an ether, an ester, an anhydride, an aldehyde, a ketone, or a carboxylic acid.
- the hydrogen atom also may be replaced by a nitrogen atom to form, for example, an amide or a nitro functionality.
- the hydrogen atom may be replaced with a sulfur atom to form, for example, a thio group or a sulfo group.
- pharmaceutically acceptable salt embraces alkali metal salts and addition salts of free acids or free bases.
- the nature of the salt is not critical, provided that it is pharmaceutically acceptable. Mixtures of two or more pharmaceutically acceptable salts may also be used.
- Suitable pharmaceutically acceptable acid addition salts of the therapeutic compounds discussed herein may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acid.
- suitable organic acids include aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic, and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, ?-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, b-hydroxybutyric, galactaric, and galactu
- Suitable pharmaceutically acceptable base addition salts of the therapeutic compounds discussed herein include metallic salts, organic salts, and ammonium salts. More preferred metallic salts include, but are not limited to, alkali metal (group la) salts, alkaline earth metal (group Ila) salts, and salts made from other physiological acceptable metals. Such salts include, for example, aluminum, calcium, lithium, magnesium, potassium, cesium, sodium, copper, iron, silver, and zinc salts.
- Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, tromethamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N- methylglucamine), and procaine.
- a sodium, potassium, calcium, or magnesium salt it is more preferred to use a sodium, potassium, calcium, or magnesium salt.
- an ammonium salt is more preferred.
- a lithium salt is more preferred.
- a zinc salt is more preferred. All of the foregoing salts may be prepared by conventional means from the corresponding therapeutic compounds discussed herein by reacting, for example, the appropriate acid or base with the compounds.
- a phosphonium salt having the formula [(C 6 H 5 ) 3 P + -(CH 2 ) 10 CO 2 CH 3 ]Bf was prepared. Approximately 3.51 g (13.39 mmol) of triphenylphosphine (i.e., (C 6 H 5 ) 3 P, Cat. No. T8,440-9, Aldrich Chemical Co., Milwaukee, WI) and 3.0 g (10.74 mmol) of methyl 11-bromo undecanoate (i.e., Br(CH 2 ) 10 CO 2 CH 3 , Cat. No. 44,746-3, Aldrich) were combined in the presence of 80 ml of acetonitrile (CH 3 CN).
- triphenylphosphine i.e., (C 6 H 5 ) 3 P, Cat. No. T8,440-9, Aldrich Chemical Co., Milwaukee, WI
- 3.0 g (10.74 mmol) of methyl 11-bromo undecanoate i.e.,
- the phosphonium salt was reacted with a base to form a mixture containing a ylide having the formula (C 6 H 5 ) 3 PCH(CH 2 ) 9 CO 2 CH 3 .
- a base Approximately 1.62 g (3 mmol) of the phosphonium salt was placed into a mixture containing 15 ml of dry tetrahydrofuran (THF) and 5 ml of dry hexamethylphosphoramide (HMPA, i. e. , [N(CH 3 ) 2 ] 3 PO, Cat. No. HI, 160-2, Aldrich).
- THF dry tetrahydrofuran
- HMPA dry hexamethylphosphoramide
- LiHMDS lithium hexamethyldisilazane
- aqueous ammonium acetate having a pH of 7 was first added to the reaction mixture to hydrolyze the excess ylide. Afterward, the methyl ester fatty acid product was extracted twice from the reaction mixture with hexane (between about 175 ml and 350 ml). The hexane mixture was then dried over anhydrous sodium sulfate (about 10 g per 100 ml of total mixture, including the hexane), and filtered. The hexane was evaporated from the mixture under a slight vacuum to form a residual liquid containing the methyl ester fatty acid product.
- the residual liquid was then separated on a homemade silica gel gravity chromatography column using a hexane/dichloromethane eluant (the volumetric ratio of hexane to dichloromethane in the solvent was 7:3). Approximately 220 mg of the methyl ester fatty of cl 1, tl3- eicosadienoic acid was obtained. The composition was verified using gas chromatography/mass spectroscopy.
- the methyl ester of cl 1, tl3-eicosadienoic acid prepared in Example 1 was hydrolyzed to form cl l,tl3-eicosadienoic acid.
- Approximately 200 mg (0.62 mmol) of the methyl ester was combined with 856 mg (6.2 mmol) of K 2 CO 3 in 15 ml of an aqueous solution containing 20% (by volume) methanol. This mixture was stirred at room temperature for 48 hours, and neutralized with an aqueous solution containing 10% (by weight) HCl.
- the free fatty acid was extracted with 150 ml ethyl acetate, and then the ethyl acetate was evaporated. This yielded approximately 130 mg of cl l,t 13 -eicosadienoic acid.
- linoleic acid i.e., t9,tl2-octadecadienoic acid, Cat. No. L-1376, Sigma Chemical Co., St. Louis, Missouri
- soybean lipooxygenase Cat. No. L-8383, Sigma Chemical
- each fatty acid compound contained the crude homogenate suspended in a buffer solution containing (1) 25 mM Tris, (2) sufficient HCl to impart a pH of 8.1, (3) 0.25 M sucrose, and (4) 1% (weight/volume) of 3-[3- cholamidopropyl)dimethylammonio]-l-propane-sulfonate (also known as "CHAPS," Sigma, St. Louis, Missouri).
- a buffer solution containing (1) 25 mM Tris, (2) sufficient HCl to impart a pH of 8.1, (3) 0.25 M sucrose, and (4) 1% (weight/volume) of 3-[3- cholamidopropyl)dimethylammonio]-l-propane-sulfonate (also known as "CHAPS,” Sigma, St. Louis, Missouri).
- Each sample contained about 2-10 ⁇ g of protein from the homogenized cells.
- the fatty acid compound was added to the samples in varying concentrations of from 0.001 tolOO ⁇ M. The samples
- Table 1 shows the results.
- the cl l,tl3-eicosadienoic acid inhibited COX-2, and was selective to COX-2 in preference to COX-1 (the ratio of the IC 50 's for COX-1 to COX-2 was at least about 3.8).
- the methyl ester of cl l,tl3-eicosadienoic acid was inactive toward inhibiting COX-2, it was also inactive toward inhibiting COX- 1 (unlike the methyl ester of c9,tl 1 -CLA, which did have a measurable inhibiting effect toward COX-1).
- Table 1 also shows that the 13(S)hydroxy-c9,tl l-(+)coriolic acid had an inhibiting effect on COX-2, and was inactive toward inhibiting COX-1.
- Table 1 Comparison of the Extent to which Various Fatty Acid Compounds Inhibit COX-1 and COX-2 Fatty Acid Compound IC 50 ( ⁇ M) 1
- IC 50 is the concentration of fatty acid compound necessary to inhibit 50% of the enzyme's (i.e., COX-1 or COX-2) activity.
- CLA is conjugated linoleic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14303199P | 1999-07-09 | 1999-07-09 | |
US143031P | 1999-07-09 | ||
PCT/US2000/040138 WO2001003688A2 (en) | 1999-07-09 | 2000-06-07 | Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1231913A2 true EP1231913A2 (en) | 2002-08-21 |
Family
ID=22502304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00951029A Withdrawn EP1231913A2 (en) | 1999-07-09 | 2000-06-07 | Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1231913A2 (ja) |
JP (1) | JP2003506324A (ja) |
AU (1) | AU6402700A (ja) |
WO (1) | WO2001003688A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2304906A1 (en) * | 2000-04-07 | 2001-10-07 | 1411198 Ontario Limited | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
IL142537A0 (en) | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of autoimmune diseases |
JP2003155231A (ja) * | 2001-11-20 | 2003-05-27 | Kikkoman Corp | 医薬及び抗アレルギー剤 |
US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
JP5198865B2 (ja) * | 2005-08-26 | 2013-05-15 | カルピス株式会社 | 筋肉痛抑制剤 |
JPWO2007108042A1 (ja) * | 2006-03-15 | 2009-07-30 | 株式会社トロピカルテクノセンター | 抗炎症剤 |
EP2444086A1 (en) * | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
JP2012111720A (ja) * | 2010-11-25 | 2012-06-14 | Fuji Flavor Kk | 5−ウンデセン酸の製造方法 |
JP6347734B2 (ja) * | 2014-12-05 | 2018-06-27 | 株式会社佐藤園 | 茶由来シクロオキシゲナーゼ−2阻害剤 |
US10751314B2 (en) | 2016-07-08 | 2020-08-25 | Stepan Specialty Profducts, Llc | Compositions comprising rumenic acid-rich conjugated linoleic acid for joint health |
US20230067205A1 (en) * | 2020-07-29 | 2023-03-02 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674901A (en) * | 1995-06-01 | 1997-10-07 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
AU718069B2 (en) * | 1993-05-28 | 2000-04-06 | Suntory Holdings Limited | Prevention and improvement of medical symptoms caused by leucotriene B4 |
GB9621630D0 (en) * | 1996-10-17 | 1996-12-11 | Kappa Pharmaceuticals Ltd | Treatment of skin disorders |
WO1998019675A1 (en) * | 1996-11-05 | 1998-05-14 | Wisconsin Alumni Research Foundation | Use of conjugated linoleic acid to enhance natural killer lymphocyte function |
US6160141A (en) * | 1997-02-18 | 2000-12-12 | Seidel; Michael C. | Synthesis of conjugated eicosadienoic acid |
DE19718245C5 (de) * | 1997-04-30 | 2004-11-11 | Cognis Deutschland Gmbh & Co. Kg | Synthetische Triglyceride auf Basis konjugierter Linolsäure, Verfahren zu deren Herstellung und deren Verwendung |
JP2001525364A (ja) * | 1997-12-12 | 2001-12-11 | パーデュー・リサーチ・ファンデーション | 糖尿病を治療する方法及び組成物 |
US6077525A (en) * | 1998-04-10 | 2000-06-20 | The George Washington University | Use of conjugated linoleic acids |
AU5561999A (en) * | 1998-08-13 | 2000-03-06 | Wistar Institute, The | Methods for reducing atherosclerotic plaques |
GB9828379D0 (en) * | 1998-12-22 | 1999-02-17 | Unilever Plc | Skin care composition |
US6602908B2 (en) * | 1999-04-01 | 2003-08-05 | Michael C. Seidel | Suppression of carcinoma using high purity conjugated fatty acid |
WO2000067596A1 (en) * | 1999-05-07 | 2000-11-16 | Trustees Of Tufts College | Immune stimulating dietary supplement and methods of use thereof |
JP3207824B2 (ja) * | 1999-05-28 | 2001-09-10 | リノール油脂株式会社 | 共役リノレン酸を有効成分とする乳癌抑制剤 |
US6077868A (en) * | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
-
2000
- 2000-06-07 WO PCT/US2000/040138 patent/WO2001003688A2/en not_active Application Discontinuation
- 2000-06-07 AU AU64027/00A patent/AU6402700A/en not_active Abandoned
- 2000-06-07 JP JP2001508969A patent/JP2003506324A/ja not_active Withdrawn
- 2000-06-07 EP EP00951029A patent/EP1231913A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0103688A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001003688A2 (en) | 2001-01-18 |
AU6402700A (en) | 2001-01-30 |
WO2001003688A3 (en) | 2002-06-20 |
JP2003506324A (ja) | 2003-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2427415B1 (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
JP5552313B2 (ja) | 脂質化合物 | |
AU2006242914B2 (en) | New DHA derivatives and their use as medicaments | |
EP2217224B1 (en) | Lipid compounds for use in cosmetic products, as food supplement or as a medicament | |
RU2444518C2 (ru) | ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО | |
EP2419399B1 (en) | Compositions and methods for the treatment of inflammation | |
TWI578984B (zh) | 使用油脂化合物類之治療方法 | |
WO2001003688A2 (en) | Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds | |
JP2010509204A (ja) | 脂肪酸アルコール | |
JP2011502113A (ja) | 新規のdha誘導体およびその医薬品としての用途 | |
JP2024122966A (ja) | 芳香族化合物およびその医薬用途 | |
JPH0840981A (ja) | エイコサペンタエノイルグリセライド | |
EP0130882B1 (fr) | Dérivés de l'acide bicyclo (3.2.1.) octane carboxylique, leur procédé de préparation et leur application thérapeutique | |
US20050101572A1 (en) | Novel carnitine conjugates as dual prodrugs and uses thereof | |
RU2507193C2 (ru) | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) | |
CN101007796A (zh) | 新型五元杂环化合物及其制备方法和医疗用途 | |
Bzdęga | Cannabidiol–a phytocannabinoid that widely affects lipid metabolism and inflammation development in the heart | |
JPH0822817B2 (ja) | エイコサペンタエノイルグリセライド含有脂質低下剤 | |
JPH07502260A (ja) | 新規ロイコトリエン−b↓4−アンタゴニスト、その製法及び医薬品としてのその使用 | |
WO2003002586A1 (fr) | Derives de [4-(4-cyanobenzoyl)phenyl]glycofuranoside, utilisation en tant que medicament, procede d'obtention et compositions pharmaceutiques les contenant | |
WO2003002585A1 (fr) | Derives de [4-(4-cyanobenzoyl)phenyl]glycopyranoside, utilisation en tant que medicament, procede d'obtention et compositions | |
WO2010069859A1 (en) | Cyclohexanecarboxamide derivatives useful as inhibitors of cholesteryl ester transfer protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020205 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060113 |